Skip to main content
PMC home page
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
editorial
. 2017 Jan 1;108(1):e95–e97. doi: 10.17269/CJPH.108.5852

The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country

Howard H Feldman 115,215,✉, Carole A Estabrooks 315
PMCID: PMC6975213  PMID: 28425906

Abstract

In the next 15 years, Canada is predicted to face a doubling in its population affected by dementia. By 2038, an estimated 1.1 million Canadians will be experiencing dementia, with unprecedented impact on social, economic and health landscapes. In September 2015, the Canadian Academy of Health Sciences convened a Forum, with the specific thematic goals of reviewing progress towards effective dementia treatment and prevention, improved systems of care, advanced living and built environments, and impactful technology developments. The orientation of the Forum was to focus on potential solutions and advances in these areas. These areas are integral to the goal of a national end-to-end program, where all affected Canadians can be optimally supported in their communities and receive quality of care - regardless of where they live or who they are.

Key Words: Dementia, prevention, national strategy, services

Footnotes

Conflict of Interest: In the last 3 years, Dr. Feldman has provided consultative services through service agreements with University of British Columbia and University of California, San Diego to Eli Lilly, Tau Rx, Merck, Biogen, lonis, and Arena Pharmaceuticals. He has served as a member of a Data Safety Monitoring Board for Eisai Pharmaceuticals and Diagnostic Monitoring Committee for Cenentech/ Banner Health. He has also served as member of research policy committee for the Alzheimer’s Society of Canada and the scientific advisory board of the Tau Consortium. He currently serves on the Research Executive Committee of the Canadian Consortium of Neurodegeneration and Aging funded by the Canadian Institutes of Health Research and is Director of the Alzheimer Disease Cooperative Study funded through the National Institute on Aging. Dr. Estabrooks has no conflicts to declare.

References

  • 1.Alzheimer Society of Canada. Dementia Numbers in Canada. 2017. [Google Scholar]
  • 2.Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013;369(24):2275–77. doi: 10.1056/NEJMp1311405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Alzheimer Society of Canada. Rising Tide: The Impact of Dementia on Canadian Society. 2010. [Google Scholar]
  • 4.Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349(9068):1793–96. doi: 10.1016/S0140-6736(97)01007-6. [DOI] [PubMed] [Google Scholar]
  • 5.Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015: The Global Impact of Dementia–An Analysis of Prevalence, Incidence, Cost and Trends. 2015. [Google Scholar]
  • 6.Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366(9503):2112–17. doi: 10.1016/S0140-6736(05)67889-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med. 2014;275(3):229–50. doi: 10.1111/joim.12178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21. doi: 10.1056/NEJMoa1312889. [DOI] [PubMed] [Google Scholar]
  • 9.Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–33. doi: 10.1056/NEJMoa1304839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: An analysis of population-based data. LancetNeurol. 2014;13(8):788–94. doi: 10.1016/S1474-4422(14)70136-X. [DOI] [PubMed] [Google Scholar]
  • 11.Sindi S, Mangialasche F, Kivipelto M. Advances in the prevention of Alzheimer’s disease. F1000Prime Rep. 2015;7:50. doi: 10.12703/P7-50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet. 2015;385(9984):2255–63. doi: 10.1016/S0140-6736(15)60461-5. [DOI] [PubMed] [Google Scholar]
  • 13.Bergman H. Meeting the Challenge of Alzheimer’s Disease and Related Disorders: A Vision Focused on the Individual, Humanism, and Excellence. 2009. [Google Scholar]
  • 14.Morgan DG, Crossley M, Kirk A D C, Stewart N, Biem J, et al. Improving access to dementia care: Development and evaluation of a rural and remote memory clinic. Aging Ment Health. 2009;13(1):17–30. doi: 10.1080/13607860802154432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alzheimer Society of Canada. Dementia Friends Canada. 2016. [Google Scholar]
  • 16.Alzheimer Society of British Columbia. Dementia-Friendly Communities. 2016. [Google Scholar]
  • 17.Chalmers J. Dementia Friendly City Initiative Halifax. 2014. [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES